U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07090031) titled 'Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer' on July 22.
Brief Summary: 5-Fluorouracil (5-FU) based chemoradiotherapy is regarded a standard perioperative treatment in locally advanced rectal cancer, but the effective rate still low. We investigate oral TAS-102 plus oxaliplatin concurrent radiotherapy for stage II or III local advanced rectal cancer.
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
EFS
pCR Rate
Intervention:
DRUG: TAS-102 in combination with oxaliplatin
Induction : TAS102 35mg/m2, twice a day for 5 days, on 1st, 3rd, 5th week; Oxliplat...